Y-Intercept (HK)’s Jade Biosciences JBIO Stock Holding History

Y-Intercept (HK)’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,131	Closed	-$353K	–	1705
2026 Q1	$353K	Buy	+25,131	New	+$364K	0.01%	1339

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Y-Intercept (HK)'s JBIO Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 25,131 shares — an estimated $353K sold.

Y-Intercept (HK) first reported a position in JBIO in Q1 2026 and held it in 1 quarter. The position peaked at $353K in Q1 2026. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

Y-Intercept (HK) reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 25,131 Jade Biosciences shares in Q2 2026, an estimated $353K.
Y-Intercept (HK) first reported a position in Jade Biosciences in Q1 2026 and held it in 1 quarter.
Y-Intercept (HK)'s Jade Biosciences position peaked at $353K in Q1 2026.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.